Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study

被引:30
作者
Fu, Shau-Huai [1 ,2 ,3 ]
Wang, Chen-Yu [4 ,5 ,6 ]
Hung, Chih-Chien [1 ]
Lee, Chia-Che [3 ]
Yang, Rong-Sen [3 ]
Huang, Chuan-Ching [3 ]
Farn, Chui-Jia [3 ]
Lin, Wei-Hsin [3 ]
Chen, Ho-Min [7 ]
Hsiao, Fei-Yuan [4 ,5 ,8 ]
Lin, Jou-Wei [9 ]
Li, Chung-Yi [2 ,10 ,11 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Orthoped, Yunlin Branch, Touliu, Yunlin, Taiwan
[2] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, 138 Sheng Li Rd, Tainan 704, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Orthoped, Taipei, Taiwan
[4] Natl Taiwan Univ, Coll Med, Sch Pharm, Taipei, Taiwan
[5] Natl Taiwan Univ, Coll Med, Grad Inst Clin Pharm, Taipei, Taiwan
[6] Natl Taiwan Univ Hosp, Dept Pharm, Yunlin Branch, Touliu, Yunlin, Taiwan
[7] Natl Taiwan Univ, Hlth Data Res Ctr, Taipei, Taiwan
[8] Natl Taiwan Univ Hosp, Dept Pharm, Taipei, Taiwan
[9] Natl Taiwan Univ Hosp, Cardiovasc Ctr, YunlinBranch, Touliu, Yunlin, Taiwan
[10] China Med Univ, Coll Publ Hlth, Dept Publ Hlth, Taichung, Taiwan
[11] Asia Univ, Coll Med & Hlth Sci, Dept Healthcare Adm, Taichung, Taiwan
关键词
osteoporosis; denosumab; bisphosphonate; discontinuation; fractures; VERTEBRAL FRACTURES; DENOSUMAB DISCONTINUATION; POSTMENOPAUSAL WOMEN; TRIAL; PERSISTENCE; REDUCTION; THERAPY; MEN;
D O I
10.1111/joim.13354
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background To compare the risks of major osteoporotic, vertebral, and non-vertebral fractures between patients who discontinued anti-osteoporosis medications. Methods We conducted a comparative effectiveness study with a nationwide population-based cohort study design. Patients aged >= 50 years admitted between 2012 and 2015 for incident hip fractures and receiving denosumab or bisphosphonates with sufficient compliance for at least 1 year were included. Patients were categorized into persistent or non-persistent denosumab or bisphosphonates users based on their subsequent use pattern. The main outcomes were subsequent hospitalizations for a major osteoporotic, vertebral or non-vertebral fracture. Multivariate, time-varying Cox proportional hazards model was used to evaluate the risk of major outcomes. Results Compared with persistent denosumab users, non-persistent denosumab users had a significantly higher risk of major osteoporotic fractures (hazard ratio [HR] = 1.60; 95% confidence interval [CI], 1.20-2.14), vertebral fractures (HR = 2.18; 95% CI, 1.46-3.24) and death (HR = 3.57; 95%CI, 2.63-4.84). However, the increased risk of fracture was not found in both persistent and non-persistent bisphosphonates users. Noteworthy, the increased risk of vertebral fractures in non-persistent denosumab users was more pronounced within 1 year post-discontinuation (HR = 2.90; 95% CI, 1.77-4.74) and among patients who discontinued from 2-year denosumab therapy (HR = 3.58; 95% CI, 1.74-7.40). Discussion Discontinuation of denosumab resulted in an increased risk of major osteoporotic fractures, especially vertebral fractures. The increased risk tends to reveal within 1 year post-discontinuation and be greater after a longer treatment duration. Notably, only fracture with hospitalization was identified as our research outcome, the real risk of osteoporotic fracture post discontinuation is believed to be higher, especially for vertebral fracture.
引用
收藏
页码:1194 / 1205
页数:12
相关论文
共 35 条
[11]   Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday [J].
Curtis, J. R. ;
Westfall, A. O. ;
Cheng, H. ;
Delzell, E. ;
Saag, K. G. .
OSTEOPOROSIS INTERNATIONAL, 2008, 19 (11) :1613-1620
[12]   Survival analysis: time-dependent effects and time-varying risk factors [J].
Dekker, Friedo W. ;
de Mutsert, Renee ;
van Dijk, Paul C. ;
Zoccali, Carmine ;
Jager, Kitty J. .
KIDNEY INTERNATIONAL, 2008, 74 (08) :994-997
[13]   Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States [J].
Durden, Emily ;
Pinto, Lionel ;
Lopez-Gonzalez, Lorena ;
Juneau, Paul ;
Barron, Richard .
ARCHIVES OF OSTEOPOROSIS, 2017, 12 (01)
[14]  
Hsiao FY, 2007, J FOOD DRUG ANAL, V15, P99
[15]   Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis [J].
Karlsson, L. ;
Lundkvist, J. ;
Psachoulia, E. ;
Intorcia, M. ;
Strom, O. .
OSTEOPOROSIS INTERNATIONAL, 2015, 26 (10) :2401-2411
[16]   Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis [J].
Kozma, Chris M. ;
Dickson, Michael ;
Phillips, Amy L. ;
Meletiche, Dennis M. .
PATIENT PREFERENCE AND ADHERENCE, 2013, 7 :509-515
[17]   Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports [J].
Lamy, O. ;
Fernandez-Fernandez, E. ;
Monjo-Henry, I. ;
Stoll, D. ;
Aubry-Rozier, B. ;
Benavent-Nunez, D. ;
Aguado, P. ;
Gonzalez-Rodriguez, E. .
OSTEOPOROSIS INTERNATIONAL, 2019, 30 (05) :1111-1115
[18]   Underestimation of Vertebral Fractures After Denosumab Discontinuation [J].
Lamy, Olivier ;
Gonzalez-Rodriguez, Elena .
JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 (03) :547-547
[19]   Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report [J].
Lamy, Olivier ;
Gonzalez-Rodriguez, Elena ;
Stoll, Delphine ;
Hans, Didier ;
Aubry-Rozier, Berengere .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (02) :354-358
[20]   Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis A Population-Based Cohort Study [J].
Lyu, Houchen ;
Yoshida, Kazuki ;
Zhao, Sizheng S. ;
Wei, Jie ;
Zeng, Chao ;
Tedeschi, Sara K. ;
Leder, Benjamin Z. ;
Lei, Guanghua ;
Tang, Peifu ;
Solomon, Daniel H. .
ANNALS OF INTERNAL MEDICINE, 2020, 173 (07) :516-+